Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 31, 2023 18:20 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022...
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
January 09, 2023 13:28 ET
|
Sarepta Therapeutics, Inc.
- The Company expects to exceed 2022 full-year guidance for net product revenues - Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million...
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 30, 2022 17:58 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 30, 2022 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022...
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
November 28, 2022 07:00 ET
|
Sarepta Therapeutics, Inc.
– Regulatory action date of May 29, 2023 – SRP-9001 would be the first gene therapy for Duchenne, a one-time treatment designed to treat the underlying cause of DMD by delivering a functional...
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
November 23, 2022 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
November 02, 2022 16:05 ET
|
Sarepta Therapeutics, Inc.
Total revenues, which consist of net product revenues and collaboration revenues, for the third quarter 2022 totaled $230.3 million Net product revenues for the third quarter 2022 totaled $207.8...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2022 18:00 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2022...
Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
October 26, 2022 08:30 ET
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial...